SCHEMBL4554045

SCHEMBL4554045

COCOc1ccc(OCC2CO2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
TP53 P04637 3/20 0.62
TSHR P16473 3/20 0.62
MAPT P10636 2/20 0.62
HPGD P15428 2/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
HIF1A Q16665 2/20 0.62
CYP1A2 P05177 1/20 0.62
PPARG P37231 1/20 0.62
TDP1 Q9NUW8 2/20 0.61
PKM P14618 2/20 0.58
LMNA P02545 1/20 0.57
GAA P10253 1/20 0.57
CYP3A4 P08684 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
GLA P06280 1/20 0.47
DRD4 P21917 4/20 0.41
FGFR1 P11362 1/20 0.40
SRC P12931 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4441325 1.00 ALDH1A1 (0.62) ALDH1A1TP53TSHRMAPTHPGD
SCHEMBL4431581 1.00 ALDH1A1 (0.62) ALDH1A1TP53TSHRMAPTHPGD
SCHEMBL15838963 0.95 ALDH1A1 (0.57) ALDH1A1TP53TSHRMAPTHPGD
SCHEMBL20080455 0.89 ALDH1A1 (0.82) ALDH1A1TP53TSHRMAPTHPGD
SCHEMBL14088749 0.88 TDP1 (0.70) ALDH1A1TP53TSHRMAPTHPGD
SCHEMBL5207477 0.88 ALDH1A1 (0.57) ALDH1A1TP53TSHRMAPTHPGD
SCHEMBL20677146 0.86 TDP1 (0.79) ALDH1A1TP53TSHRMAPTHPGD
SCHEMBL21094081 0.86 TDP1 (0.79) ALDH1A1TP53TSHRMAPTHPGD
SCHEMBL50264 0.86 TDP1 (0.79) ALDH1A1TP53TSHRMAPTHPGD
SCHEMBL10500015 0.85 ALDH1A1 (0.62) ALDH1A1TP53TSHRMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207174-B2 Beta-3 adrenergic receptor agonists; urinary tract infections, incontinence, gastrointestinal disorders, dysmenorrhea, obesity; tocolytic, anxiolytic, antidiabetic agents; antidepressants; 4-(2-hydroxy-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propoxy)phenol 4SC AG (DE) 2012-06-26 US disclosed
EP-2118086-A1 ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEREOF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS 4SC AG (DE) 2009-11-18 EP disclosed
US-20080249114-A1 ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS SCHWARZ PHARMA AG (DE) 2008-10-09 US disclosed
WO-2008090140-A1 ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEREOF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS 4SC AG (DE) 2008-07-31 WO disclosed
EP-1947103-A1 Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments 4SC AG (DE) 2008-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249114-A1 ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS ADRB3, ADRB1, ADRB2 ALDH1A1 1070/4885TP53 3884/4885TSHR 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.